Skip To Main Content
Wenying Deng on Muck Rack

Wenying Deng

As seen in: Environmental Health Perspectives, Nature, Cell Reports Medicine, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wenying

Contact Wenying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

|
By Joshua Richter, Madhav V. Dhodapkar, Mansi Shah, Joaquín Martínez-López, Mina Awad, C. Akunna Otele, Mengying Li, Christian Hampp, Wenying Deng, Katherine Knorr Verified, Tito Roccia, Glenn S. Kroog, Paula Rodríguez-Otero
| Nature Verified
Abstract Patients with multiple myeloma are at increased risk of infection, highlighting the importance of evidence-based strategies for prevention, monitoring, and management of infections. In this post hoc analysis, we characterized infection events in 117 patients treated with linvoseltamab 200 mg in the Phase 1/2 LINKER-MM1 study (NCT03761108).
Open in Who Shared Issue with article?

Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study

|
By Liangyu Bie, Chen Wei, Suxia Luo, Zhiwei Gu, Yijie Ma, He Zhang, Jing Li, Wenying Deng, Ning Li, Shuailei Dong, Qingxin Xia
| Cell Reports Medicine Verified
Keywords benmelstobart plus anlotinib and chemotherapy HER2-negative G/GEJ phase 2 study first-line therapy PD-L1 PBIC profile Introduction Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma is the fifth most prevalent and the fifth most lethal cancer worldwide.1 Despite the availability of early screening and local resection, most diagnoses occur at an advanced stage, and the prognosis of patients with G/GEJ cancer remains poor.2 Notably, pivotal clinical trials, such as CheckMate...
Open in Who Shared Issue with article?

Research advances in fusion protein-based drugs for DM

|
By Wenying Deng, Zeyi Zhao, Tao Zou, Tongdong Kuang
| Dove Medical Press
Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 17 Authors Deng W , Zhao Z , Zou T, Kuang T , Wang J Received 10 July 2023 Accepted for publication 22 December 2023 Published 23 January 2024 Volume 2024:17 Pages 343—362 DOI https://doi.org/10.2147/DMSO.S421527 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Konstantinos Tziomalos Wenying Deng,1,* Zeyi Zhao,1,* Tao Zou,2 Tongdong...
Open in Who Shared Issue with article?
See all 4 articles